Two Research Peptides, One Sleep Question

The short version

Peptide Ways is a reading desk, not a store. It collects what the published research literature actually says about two peptides that keep coming up in conversations about sleep, recovery, and anxiety: DSIP (Delta Sleep-Inducing Peptide) and Selank. A peptide is just a short chain of amino acids — the same building blocks that make up proteins, only far smaller. Each of these two has been studied because it appears to act on the nervous system in ways that might matter for how the brain winds down, handles stress, or recovers from it.

This guide does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which species, and how far that evidence really reaches. Honest answer: for DSIP, not very far and not very consistently. For Selank, further — but still mostly in animals and a small set of Russian clinical studies. Neither is an approved medicine in the United States. We do not sell anything, we do not give medical advice, and we never list a human dose.

What are research peptides?

Proteins in your body — a sleep-regulating hormone, a signaling molecule in the gut, a receptor on a nerve cell — are long chains of amino acids folded into a shape. A peptide is a much shorter chain of the same building blocks, sometimes only three or four links long. Because they are small and specific, peptides can act like keys that fit particular locks (receptors or enzymes) on the surface of cells or inside them, nudging certain processes on or off.

A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, occasionally in early human pilots — but has not been approved by a regulator as a medicine. Sellers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in people are usually unestablished or poorly characterized. When this site reports a number, it reports it the way the study did — for example, infused at 25 nanomoles per kilogram intravenously in men — never as a recommendation.

How these two fit into sleep and recovery research

DSIP and Selank arrive at the sleep-and-recovery question from very different directions.

DSIP is the lead. It was isolated from the cerebral venous blood of sleeping rabbits in 1977 and named for its ability to enhance slow-wave, or delta, brain activity when infused directly into rabbit brains ^[6]. The name stuck even as the evidence for its role in human sleep stayed stubbornly thin. A 2006 review in the Journal of Neurochemistry described it as "a still unresolved riddle" whose sleep evidence is "extremely poorly documented and still weak" ^[2]. That is worth leading with: the peptide that defines this desk's angle is also the most honestly uncertain one on it. It is naturally occurring, it touches the stress axis, it has been tested in a handful of small human pilots — and it may do nothing for a large share of people who try it.

Selank approaches the same territory from the anxiety side. Rather than a sleep signal, it is a synthetic analog of an immune peptide (tuftsin), extended to slow its breakdown, and studied as a non-benzodiazepine anxiolytic. In animal and limited human work it appears to quiet anxious arousal through GABAergic and enkephalin pathways ^[8] — which matters for sleep because anxious mental noise is one of the most common reasons people stay awake. Whether calming anxiety translates to better sleep is a knock-on question the research does not fully answer.

Together the two sketch the sleep-and-recovery question from complementary sides: a direct (if inconsistent) sleep signal and an anxiety-quieting mechanism. Use the directory to read each one, or compare these peptides side by side.

A note on how this desk reads the literature

Peptide Ways is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source across both. Where the evidence is thin, single-lab, single-region, or preclinical, we say so plainly — that is part of the record, not a footnote to it. We describe research findings and the cited cautions that come with them; where the community experience diverges meaningfully from the published record, we report those signals clearly labeled as anecdotal.

The goal is a quiet, accurate map of what is known, what is genuinely unknown, and what is being sold past what the evidence supports. For these two peptides, that last category is wide.